Trial · NCT04276090
Registered outcomes12
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Percent Completion of 1st Cycle of Hepatic Artery Chemotherapy | approximately 4 weeks | The percent of patients who complete the 1st cycle of hepatic artery chemotherapy will be tabulated. This is a conglomerate safety endpoint which is a surrogate for any complication that prevents delivery of hepatic artery chemotherapy via the device combination. |
| Secondary | 30-day Postoperative Serious Adverse Events Related to Pump Implantation | 30 days | Tabulation of CTCAE serious adverse events attributed to pump implantation |
| Secondary | 30-day Catheter Malfunction Due to Tubing Disconnect | 30 days | Quantify the percent of patients with inability to meet primary outcome due to catheter disconnects. |
| Secondary | 30-day Catheter Malfunction Due to Inability to Access Pump | 30 days | Quantify the percent of patients with inability to meet primary outcome due to inability to access pump. |
| Secondary | Percent of Patients That Require Secondary Intervention in Order to Obtain Primary Pump Function. | Approximately 4 weeks | Percentage of patients who need secondary intervention (IR embolization, revision of pump or tubing) to achieve primary pump function. |
| Secondary | Percent of Screened Patients That Are Declined Due to High Risk of Failure as Determined by the Psychosocial Assessment Tool. | Immediate, determined at screening visit | Patients are screen using a psychosocial assessment tool for high risk of hepatic artery pump loss/failure, percent declined will be tabulated. |
| Secondary | Percent Pump Loss Due to Inability to Attend Scheduled Followup Appointments. | Approximately 6 months | Percent of patients that experience pump loss/failure due to inability to attend scheduled followup appointments will be tabulated. |
| Secondary | Number of Interventions (Phone Calls) to Assure Patients Attend Followup Appointments. | 6 months | The number of staff contacts (phone calls) to assure patients keep their followup visits will be tabulated. |
| Secondary | Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 3 Months. | 3 months | The percentage of patients who remain on pump chemotherapy at 3 months will be tabulated. |
| Secondary | Overall Response Rate at 6 Months | 6 months | RECIST v1.1 will be used to assess overall response rate at 6 months. |
| Secondary | Percent of Patients Who Are Downstaged and Undergo Surgery | 6 months | The percent of patients who are downstaged and undergo surgery will be tabulated. |
| Secondary | Percent of Patients Who Remain on Hepatic Artery Infusion Pump Chemotherapy at 6 Months. | 6 months | The percentage of patients who remain on pump chemotherapy at 6months will be tabulated. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT04276090/registered